<DOC>
	<DOCNO>NCT02147873</DOCNO>
	<brief_summary>This randomize double blind placebo control study azacitidine without birinapant subject high risk Myelodysplastic syndrome , secondary MDS myelomonocytic leukemia ( CMMoL ) naïve , azacitidine therapy . Pre-clinical mechanistic study support azacitidine may modulate pathway enable birinapant-mediated anti-tumor activity .</brief_summary>
	<brief_title>Study Azacitidine With Without Birinapant Subjects With MDS CMMoL</brief_title>
	<detailed_description>This randomize double blind placebo control study azacitidine without birinapant subject high risk Myelodysplastic syndrome , secondary MDS myelomonocytic leukemia ( CMMoL ) The primary purpose study : -To compare relative effect azacitidine plus birinapant versus azacitidine plus placebo response rate patient higher-risk MDS , secondary MDS CMMoL . The secondary purpose study compare effect azacitidine plus birinapant relative azacitidine placebo : - Hematologic improvement - Relapse free survival - Time respond - Change transfusion requirement - Duration response - Overall survival - Adverse event The exploratory objective study assess exploratory translational biomarkers antitumor effect .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>key Morphologically confirm diagnosis MDS/CMMoL accord FAB WHO classification , include RAEBt MDS/MPN International prognostic scorerevised ( IPSSR ) &gt; 3.5 ( Intermediate , High Very High ) Previously untreated hypomethylating agent MDS/CMMoL Performance status 0 , 1 2 ECOG scale Adequate renal liver function Female subject childbearing potential must negative serum pregnancy test screening within 96 hour prior first study dose . Female subject childbearing potential male subject partner childbearing potential ensure use highly effective method birth control define investigator , example , result low failure rate ( i.e. , less 1 % per year ) use consistently correctly study period 3 month follow last dose drug administer study . Key Relapsed refractory hypomethylating agent Acute myeloid leukemia ( AML ) , except patient RAEBt candidate intensive AML therapy . Participated interventional study within 4 week randomization 5 half life ( whichever longer ) . Received hematopoietic growth factor within 14 day prior screen . Prior malignancy secondary malignancy within prior 2 year ( except situ cervical cancer , squamous cell carcinoma basal cell carcinoma skin ) . know diagnosis human immunodeficiency virus chronic active Hep B C. Uncontrolled hypertension Impaired cardiac function , uncontrolled cardiac arrhythmia despite medication , clinically significant cardiac disease Lack recovery prior adverse event Grade ≤1 severity ( National Cancer Institute Common Terminology Criteria Adverse Events version 4 ) ( except alopecia ) due therapy administer prior initiation study drug dose . Nursing pregnant . Known allergy hypersensitivity formulation component Any concurrent disease and/or medical condition , opinion Investigator , would prevent subject 's participation . History cranial nerve palsy . Being treat antiTNF therapy treat antiTNF therapy within 5 halflives randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>MDS</keyword>
	<keyword>CMML</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>TL32711</keyword>
	<keyword>TL32711-0094</keyword>
	<keyword>azacitidine</keyword>
	<keyword>birinapant</keyword>
	<keyword>high risk</keyword>
	<keyword>naive</keyword>
	<keyword>double blind</keyword>
	<keyword>placebo</keyword>
	<keyword>placebo control</keyword>
	<keyword>randomize</keyword>
</DOC>